PT - JOURNAL ARTICLE AU - Mohammad Ahangari AU - Robert Kirkpatrick AU - Tan-Hoang Nguyen AU - Nathan Gillespie AU - Irish Schizophrenia Genomics Consortium AU - Kenneth S. Kendler AU - Silviu-Alin Bacanu AU - Bradley T. Webb AU - Brian C. Verrelli AU - Brien P. Riley TI - Investigating the source of increased bipolar and major depressive disorder polygenic risk in multiplex schizophrenia families AID - 10.1101/2021.11.15.21266368 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.15.21266368 4099 - http://medrxiv.org/content/early/2021/11/16/2021.11.15.21266368.short 4100 - http://medrxiv.org/content/early/2021/11/16/2021.11.15.21266368.full AB - Psychotic and affective disorders often aggregate in the relatives of probands with schizophrenia (SCZ), and genetic studies show substantial genetic correlation among SCZ, bipolar disorder (BIP) and major depressive disorder (MDD). However, the nature of this genetic overlap in polygenic risk score (PRS) analyses of multiplex families has not been fully dissected. In the current study, we investigated the polygenic risk burden of BIP and MDD in a sample of 257 multiplex SCZ families (N=1,005) and population controls (N=2,205). Furthermore, due to the strong genetic correlation among SCZ, BIP, and MDD, we examined whether increased BIP or MDD PRS in members of multiplex SCZ families can be attributed to latent genetic factors unique to BIP or MDD, or latent genetic factors that each of these two disorders share with SCZ. Our results indicate that members of multiplex SCZ families have an increased PRS for BIP and MDD, however, this observation is largely attributable to latent genetic factors that BIP or MDD share with SCZ, rather than latent genetic factors unique to them. These results provide new insight for cross-disorder PRS analyses of psychiatric disorders, by cautioning that for complete interpretation of observed cross-disorder PRS enrichment, we should account for genetic correlations across psychiatric disorders. Our findings further indicates that members of multiplex SCZ families may have an increased genetic vulnerability to both psychotic and affective disorders, and for full assessment of an individual’s genetic risk, familial backgrounds should be taken into consideration.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMA, BV, S-AB, KSK, BTW and BR were supported by R01-MH114593 (to Dr. Riley). Production of GWAS data for singleton cases and controls was supported by R01-MH083094 (to Dr. Riley). Production of GWAS data for multiplex pedigrees was supported by R01-MH062276 and R01-MH068881 (to Dr. Riley). T-HN was supported by NARSAD Young Investigator Grant 28599.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Virginia Commonwealth University Office of Research Subject Protection. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode Availability: All the scripts used in this study will be made available upon publication. We made use of various freely available software tools in this study: Plink2: https://www.cog-genomics.org/plink/2.0/ GenomicSEM: https://github.com/GenomicSEM/GenomicSEM PRS-CS: https://github.com/getian107/PRScs MiXeR: https://github.com/precimed/mixer LDSC: https://github.com/bulik/ldsc GMMAT: https://github.com/hanchenphd/GMMAT LDAK: http://dougspeed.com/ldak/ Data Availability: GWAS summary statistics for SCZ, BIP, MDD, and LDL are publicly available. PGC3-SCZ: https://www.med.unc.edu/pgc/download-results/ PGC3-BIP: https://www.med.unc.edu/pgc/download-results/ PGC2-MDD-UKB Meta-analysis: https://datashare.ed.ac.uk/handle/10283/3203 LDL: http://diagram-consortium.org/2015_ENGAGE_1KG/ GWAS-by-subtraction summary statistics generated in this study will be made publicly available upon publication.